In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent ...
Drs. Kalyan M. Shekhda1 (Royal Free Hospital, London, UK), Shaunak Navalkissoor Royal Free Hospital, London, UK), and Ashley B. Grossman (University of Oxford and Queen Mary University of London, ...
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at ...
A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Perspective Therapeutics, Inc. announced the dosing of the first patient in a new cohort of its Phase 1/2a trial assessing the safety of [212Pb]VMT01, a targeted alpha-particle therapy for melanoma ...
Researchers gain new insights into how the isotope astatine-211 interacts with resins commonly used to purify the isotope for therapeutic use Targeted Alpha Therapy (TAT) is one of the most powerful ...
BERLIN--(BUSINESS WIRE)-- Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results